Literature DB >> 6163448

Copper(II).bleomycin, iron(III).bleomycin, and copper(II).phleomycin: comparative study of deoxyribonucleic acid binding.

L F Povirk, M Hogan, N Dattagupta, M Buechner.   

Abstract

The kinetics and mechanism of binding of Cu-(II).bleomycin, Fe(III).bleomycin, and Cu(II).phleomycin to DNA were studied by using fluorometry, equilibrium dialysis, electric dichroism, and temperature-jump and stopped-flow spectrophotometry. The affinity of Cu(II).bleomycin for DNA was greater than that of metal-free bleomycin but less than that of Fe(III).bleomycin. Cu(II).bleomycin exhibited a two-step binding process, with the slow step indicating a lifetime of 0.1 s for the Cu(II).bleomycin.DNA complex. Fe(III).bleomycin binding kinetics indicated the presence of complexes having lifetimes of up to 22 s. DNA was lengthened by 4.6 A/molecule of bound Cu(II).bleomycin and by 3.2 A/bound Fe(III).bleomycin but not at all by Cu(II).phleomycin, suggesting that both bleomycin complexes intercalate while the phleomycin complex does not. However, phleomycin exhibited nearly the same specificity of DNA base release as bleomycin. These results suggest that the coordinated metal ion plays a major role in the binding of metal-bleomycin complexes to DNA but that intercalation is neither essential for DNA binding and degradation nor primarily responsible for the specificity of DNA base release by these drugs.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6163448     DOI: 10.1021/bi00506a034

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  10 in total

1.  Sequence-selective binding of phleomycin to DNA.

Authors:  K R Fox; G W Grigg; M J Waring
Journal:  Biochem J       Date:  1987-05-01       Impact factor: 3.857

2.  Zorbamycin has a different DNA sequence selectivity compared with bleomycin and analogues.

Authors:  Jon K Chen; Dong Yang; Ben Shen; Brett A Neilan; Vincent Murray
Journal:  Bioorg Med Chem       Date:  2016-09-30       Impact factor: 3.641

Review 3.  Antitumor antibiotics discovered and studied at the Institute of Microbial Chemistry.

Authors:  T Takeuchi
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

4.  Solution structure of the hydroperoxide of Co(III) phleomycin complexed with d(CCAGGCCTGG)2: evidence for binding by partial intercalation.

Authors:  Wei Wu; Dana E Vanderwall; Christopher J Turner; Silvia Hoehn; Jingyang Chen; John W Kozarich; JoAnne Stubbe
Journal:  Nucleic Acids Res       Date:  2002-11-15       Impact factor: 16.971

5.  Interaction of bleomycin with a bent DNA fragment.

Authors:  K P Nightingale; K R Fox
Journal:  Biochem J       Date:  1992-06-15       Impact factor: 3.857

6.  Minor role of lipid peroxidation in acute bleomycin toxicity in rats.

Authors:  H Muliawan; A Burkhardt; M E Scheulen; H Kappus
Journal:  J Cancer Res Clin Oncol       Date:  1982       Impact factor: 4.553

7.  X-ray crystallographic analysis of 3-(2'-phenyl-2,4'-bithiazole-4-carboxamido) propyldimethylsulphonium iodide, an analogue of the DNA-binding portion of bleomycin A2.

Authors:  R Kuroda; S Neidle; J M Riordan; T T Sakai
Journal:  Nucleic Acids Res       Date:  1982-08-11       Impact factor: 16.971

8.  Diethylpyrocarbonate and permanganate provide evidence for an unusual DNA conformation induced by binding of the antitumour antibiotics bleomycin and phleomycin.

Authors:  K R Fox; G W Grigg
Journal:  Nucleic Acids Res       Date:  1988-03-25       Impact factor: 16.971

9.  Intracellular dynamics of archaeal FANCM homologue Hef in response to halted DNA replication.

Authors:  Roxane Lestini; Sergey P Laptenok; Joëlle Kühn; Mark A Hink; Marie-Claire Schanne-Klein; Ursula Liebl; Hannu Myllykallio
Journal:  Nucleic Acids Res       Date:  2013-09-17       Impact factor: 16.971

10.  Dual gene expression cassette vectors with antibiotic selection markers for engineering in Saccharomyces cerevisiae.

Authors:  Claudia E Vickers; Sarah F Bydder; Yuchan Zhou; Lars K Nielsen
Journal:  Microb Cell Fact       Date:  2013-10-25       Impact factor: 5.328

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.